View
49
Download
0
Category
Tags:
Preview:
DESCRIPTION
M icroPET : Radiotracer I maging of Rodents and Non- H uman Primates. Alexander K. Converse, PhD University of Wisconsin–Madison Waisman Center - Brain Imaging Core Town Hall - Thursday 2 February 2012. Radioactive Decay & Positron – Electron Annihilation. P ositron E mission T omography. - PowerPoint PPT Presentation
Citation preview
MicroPET: Radiotracer Imaging of Rodents and Non-Human Primates
Alexander K. Converse, PhDUniversity of Wisconsin–Madison
Waisman Center - Brain Imaging CoreTown Hall - Thursday 2 February 2012
Radioactive Decay & Positron – Electron Annihilation
Positron Emission Tomography
UW-Madison PET
Animal Brain PET Scanners
6 uL
3 uL
3 uL
2 uL + MR
Fig. 26 BLOOD VOLUME: Carbon monoxide imaging of hemoglobin in rat12
y = 5.05x - 4332y = 6.15x - 5423y = 6.00x - 5264
0
2000
4000
6000
8000
10000
0 1000 2000 3000Cb / CdPu
CdP
u / C
dPu
AT57AT47AT97
A
y = 5.05x - 4332y = 6.15x - 5423y = 6.00x - 5264
0
2000
4000
6000
8000
10000
0 1000 2000 3000Cb / CdPu
CdP
u / C
dPu
AT57AT47AT97
A
Fig. 25: QUANTIFICATION: Logan determination of binding of a dopamine
D2 tracer5
PHARMACOKINETIC MODELING
Fig. 24 DOPAMINE RELEASE: Time activity curves of a dopamine D2 receptor tracer in response to
amphetamine5
L R
0.4 mg/kg 0.0 mg/kgAT47
AT57
AT97
AU18
AU21
A B
0
1
2
3
4
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
3
4
0 2000 4000 6000time (s)
activ
ity (uC
i/mL)
0
1
2
3
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
0 2000 4000 6000time (s)
activ
ity (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
3
4
0 2000 4000 6000time (s)
activ
ity (uC
i/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
3
4
0 2000 4000 6000time (s)
activ
ity (uC
i/mL)
0
1
2
3
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
0 2000 4000 6000time (s)
activ
ity (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
3
4
0 2000 4000 6000time (s)
activ
ity (uC
i/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0.4 mg/kg 0.0 mg/kg
L R
0.4 mg/kg 0.0 mg/kgAT47
AT57
AT97
AU18
AU21
A B
0
1
2
3
4
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
3
4
0 2000 4000 6000time (s)
activ
ity (uC
i/mL)
0
1
2
3
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
0 2000 4000 6000time (s)
activ
ity (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
3
4
0 2000 4000 6000time (s)
activ
ity (uC
i/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
3
4
0 2000 4000 6000time (s)
activ
ity (uC
i/mL)
0
1
2
3
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
0 2000 4000 6000time (s)
activ
ity (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
3
4
0 2000 4000 6000time (s)
activ
ity (uC
i/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activity (u
Ci/m
L)
0.4 mg/kg 0.0 mg/kg
L R
0.4 mg/kg 0.0 mg/kgAT47
AT57
AT97
AU18
AU21
A B
0
1
2
3
4
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s )
activity (uCi/mL)
0
1
2
3
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
0 2000 4000 6000time (s )
activity (uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s )
activity (uCi/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s )
activity (uCi/mL)
0
1
2
3
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
0 2000 4000 6000time (s )
activity (uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s )
activity (uCi/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activity (uCi/mL)
0.4 mg/kg 0.0 mg/kg
L R
0.4 mg/kg 0.0 mg/kgAT47
AT57
AT97
AU18
AU21
A B
0
1
2
3
4
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s )
activity (uCi/mL)
0
1
2
3
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
0 2000 4000 6000time (s )
activity (uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s )
activity (uCi/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s )
activity (uCi/mL)
0
1
2
3
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
0 2000 4000 6000time (s )
activity (uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s )
activity (uCi/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activity (uCi/mL)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activity (uCi/mL)
0.4 mg/kg 0.0 mg/kg
Fig. 23. PARAMETER ESTIMATION: Time activity curves from a multiple injection study of a dopamine D2
receptor ligand in rhesus15
Fig. 19 ASTHMA: Glucose metabolism in inflammation in a rat lung10
Fig. 20 MULTIPLE SCLEROSIS: Microglial cell activation in white matter in
response to zymosan in rat11
INFLAMMATION
Fig. 21 OPIOID RECEPTORS: Kappa
opioid receptor availability in parrot
brain6
PAIN
Fig. 22 AVIAN VETERINARY
ANALGESIA: Increased glucose metabolism in
response to experimental arthritis in
parrot6
Fig. 15 STEM CELL THERAPY: Dopamine synthesis in a rhesus model pre- and post- unilateral
lesion13
Fig. 16 NEURODEGENERATION: Rat model of striatal
neurodegneration for pre- (left) and post- (right) stem cell treatment (first image from the microPET P4, 2002)
Fig. 18 L-DOPA: Recovery of AAAD activity in a rhesus model7
Fig. 17 GENE THERAPY: Dopamine synthesis pre- and post- lentiviral delivery of GDNF in a unilateral lesion rhesus model8
PARKINSON’S DISEASE
Fig. 7 CHILDHOOD ANXIETY: Dopamine D2 receptors in rhesus1
MOOD DISORDERS
Fig. 9 SEXUAL BEHAVIOR: Glucose metabolism in female marmosets
Fig. 8 CHILDHOOD ANXIETY: Glucose metabolism in rhesus9
Fig. 10 PRENATAL ALCOHOL EXPOSURE:
glucose metabolism alterations due to a
reversal task in rhesus3
Fig. 11 PRENATAL ALCOHOL EXPOSURE: Serotonin 1A receptors in
rhesus2
ADDICTIVE BEHAVIORS
Fig. 14: EATING BEHAVIORS Dopamine D2 receptor response to deep brain stimulation in
rhesus14
Fig. 12 PRENATAL ALCOHOL EXPOSURE: Image of dopamine transporter in rhesus and time activity curves4
Fig. 13 AMPHETAMINE: Blood flow alteration correlated with dopamine release in rhesus5
Radiotracers Used with the Waisman Center microPET
Design Logistics Radiochemistry Scanner Analysis
PET
Alex Converse
Director, MicroPET Imaging
Waisman Center Brain Imaging Core
akconverse@wisc.edu
Recommended